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A substantial group of patients with diabetic macular edema in our clinical prac-
tice is at high risk for profound and irreversible vision deterioration. Early identifi-
cation of modifiable factors with long-term negative impact and their management, 
close monitoring and timely adjustments in the treatment can significantly reduce 
the probability of visual disability in the individual patient. This approach can also 
provide important guidelines for proactive decision making in order to avoid the 
risk of suboptimal response and unsatisfactory outcome.
Keywords: Retinal symptoms and signs, systemic risk factors, treatment options, 
management stages
1. Introduction
The introduction of intravitreal pharmacotherapy dramatically improved the visual 
prognosis of the patients with diabetic macular edema (DME). However, the pivotal 
randomized clinical trials demonstrated that a sizable proportion of the eyes remained 
with disabling visual acuity despite intensive treatment and vigorous monitoring for 
2 years [1]. Moreover, after transition to standard clinical care for the next 3 years, the 
visual acuity worsened even in patients with significant vision gain [2]. Real-world 
studies on DME management from Europe, USA, Japan and Australia reveal significant 
differences in the registration, national policies and restrictions for the use of the medi-
cations. A common issue is a tremendous pressure on the ophthalmic care providers to 
reduce the cost of visits and treatment. This invariably has resulted in visual outcomes 
that were meaningfully inferior to those achieved in randomized controlled trials [3–8].
These data suggest that a substantial group of patients with diabetic macular 
edema in our clinical practice is at high risk for profound and irreversible vision dete-
rioration. Early identification of modifiable factors with long-term negative impact 
and their management, close monitoring and timely adjustments in the treatment 
can significantly reduce the probability of visual disability in the individual patient. 
Such a systematic approach can also provide important guidelines for proactive deci-
sion making in avoiding the risk of suboptimal response and unsatisfactory outcome.
2. Low visual acuity at baseline
Post hoc analysis of the best-corrected visual acuity (BCVA) achieved in DRCR.
net Protocol T randomized clinical trial after anti-VEGF treatment [1] demonstrated 
that 96–100% of eyes enrolled in the trial with BCVA 20/32 to 20/40 retained high 
vision after 6 months even in the presence of persistent edema. A small proportion 
Diabetic Eye Disease - From Therapeutic Pipeline to the Real World
2
- 8% of these eyes - deteriorated below 20/40 at the end of the first year and further 
5–8% worsened after 2 years, and only if the edema was persistent.The outcome 
in eyes with baseline BCVA 20/50 to 20/320 was far less – through the 24th week 
21–41% of them failed to improve over 20/50, and the results were worse if the 
edema was persistent – 31–51% of them had BCVA less than 20/40. By the end of the 
first year 11–30% of these eyes were still seeing below 20/40 and the outcome was 
worse if the edema was persistent – 33–46% remained in the low vision group. After 
2 years of anti-VEGF treatment 17–25% of these eyes did not improve over 20/50 and 
their proportion reached 46% in eyes with persistent edema. Standard clinical care 
in the next three years resulted in vision deterioration by at least one Snellen line (4.8 
letters) in the whole cohort and the proportion of eyes with BCVA less than 20/40 
increased from 16% at the end of the second year to 27%. [2]. The overall impression 
from the clinical trials and real-life practice is that significant vision gain is achiev-
able even in eyes with low baseline vision at relatively low risk of severe vision loss, 
however it requires intensive treatment and the long-term outcome is often unstable. 
In contrast, eyes with higher visual acuity at baseline have much better chance to 
retain it in the next 2 and 5- year interval with appropriate management.
3. Imaging and biomarkers
Stereoscopic examination of the retina readily reveals signs predicting slow, 
limited visual response to treatment and tendency for recurrence:
Diffuse edema, ischaemic areas in the posterior pole, hard exudates close to the 
fovea and atrophic changes in the deep layers are often associated with long-stand-
ing disease. These changes persist if pharmacotherapy was provided occasionally 
and in long intervals.
Previous laser treatment close to the macula leaves chorioretinal scars that 
slowly progress towards the fovea, particularly if the photocoagulation spots were 
confluent and with high intensity.
PDR - active proliferative disease, signs of hypo- or nonperfusion and particularly 
the presence of retinal ischaemic areas in the equatorial zone and periphery indicate 
advanced microvascular damage and carry poor visual prognosis if left untreated. 
As noted in the secondary analysis of Protocol T patients, eyes with less than severe 
nonproliferative diabetic retinopathy (EDTRS severity levels 10 to 47) had 3.1 letters 
more visual acuity improvement after treatment for 2 years compared to patients with 
inactive advanced PDR and no prior panretinal photocoagulation. [9]
Panretinal photocoagulation (PRP) for advanced PDR (EDTRS severity levels 
61 to 75) at baseline in the same clinical trial was associated with approximately 3 
letters less vision gain after 2 years [9]. This finding needs careful interpretation. 
Often, advanced PDR is associated with various stages of macular edema, and laser 
treatment that prevented the total blindness is such patients, was done years prior 
to the introduction of pharmacotherapy for the macular complication. On the other 
hand, confluent, high-intensity laser treatment applied over large areas in one or 
two sessions is associated with significant thermal trauma and can lead to inflam-
mation, worsening of the macular edema, followed by atrophic changes and vision 
deterioration that may not respond to treatment.
Glistening, taut epiretinal membranes in the posterior pole with characteristic 
folds and retinal distortion require close monitoring - they may limit the vision gain 
in response to treatment, particularly in the presence of atrophic macular changes 
(Figure 1).
Anterior–posterior vitreo-macular traction can cause edema per se and will not 
respond to intravitreal treatment. [10]
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4. Optical coherent tomography
Systematic analysis of OCT at the  initial visit provides insight into the severity and 
duration of the disease and guides the appropriate choice of treatment and regimen.
The location, size and content of intra- and subretinal fluid collections: 
Cystic spaces exceeding 200 μm involving the outer nuclear layer (ONL) are seen in 
late stage of DME and have a worse impact on macular function than smaller cysts or 
cystoid formations occurring in inner retinal layers (Figure 2b). Large cysts located 
in the perimacular area tend to extend centrally with time (Figure 3b and d). Even 
though in the early phases the visual acuity is not severely deteriorated, in the pres-
ence of other risk factors treatment has to be initiated – these patients have excellent 
chances to retain good function without major fluctuations. Lack of retinal bridges 
between the cystic spaces in the inner and outer retina is a sign of long-standing 
severe disease and is associated with poor visual prognosis despite resolution of the 
fluid post treatment (Figure 2d). Subfoveolar neurosensory detachment is seen in 
cases with more severe edema and has been associated with more active inflamma-
tory components of the disease (Figure 1a). These patients responded favorably in 
the pivotal clinical trials on anti-VEGF and dexamethasone treatment with signifi-
cant functional gains. This type of edema has a tendency to recur in chronic cases 
with interrupted intravitreal treatment, deterioration of the systemic disease or after 
cataract surgery (Figure 4).
Hyperreflective retinal foci appear as small lesions with size less than 30 μm 
with reflectivity similar to retinal nerve fiber layer and without back-shadowing over 
the underlying layers. They appear to represent subclinical lipoproteins that extrava-
sate after breakdown of inner blood–retinal barrier, although there are suggestions 
that they might be activated microglial cell, and indicate chronicity and predominant 
inflammation in the eye. Increased number of the spots indicate tendency for recur-
rence of the edema and require close monitoring (Figures 1c and 7d).
Hard exudates present in the OCT as hyperreflective intraretinal accumulations 
larger than 30 μm with back-shadowing. The deposits are thought to consist of 
lipoproteins and indicate advanced microvascular damage and chronicity. In severe 
cases they can form fibrotic lesions that are associated with visual decline, espe-
cially if located in or close to the macula (Figure 5) [11].
Disorganization of retinal inner (DRIL) and outer layers within the central 
1 mm retinal zone may not be readily distinguishable if the edema is severe and 
Figure 1. 
63 years old male, DM for 23 years, DME, PDR. a –VA decreased from 20/40 to 20/80 in two month during 
decompensation of CAD and CABG -epiretinal membrane, lamellar macular hole, severe recurrence of 
intraretinal edema with macrocysts, subsensory fluid collection; b -after 5 anti-VEGF injection –persistent 
intraretinaledema, resolved subsensoryfluid, VA 20/40, c − 27 months and 9 anti-VEGF injections later – 
persistent intraretinal edema, hyperreflective foci, epiretinal membrane, lamellar macular hole, VA 20/40; 
d –persistent macrocysts, ischemic areas, hard exudates and microaneurisms.
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associated epiretinal membranes and hyperreflective lesions, especially if there are 
media opacities (Figure 2). It is becoming evident in the course of the treatment after 
regression of the edema and explains the low visual acuity and minimal vision gain. 
DRIL has been attributed to macular capillary non-perfusion, the size and erosion 
Figure 2. 
58 years old male, nephropathy, diabetic foot, CAD, PDR, recurrent macular edema, neovascularglaucoma 
after glaucoma drainage implant (Ahmed valve). a –OCTA total retina –broad areas of hypoperfusion, 
microaneurisms, enlarged distorted foveolar avascular zone; b -severe recurrence during Leukemoid reaction, 
HbA1c 11%, VA 20/200; c -one week after anti-VEGF injection, VA 20/70; d − 3 months later -recurrence 
after treatment on Imatinib for 3 months, VA 20/100; e -one month after anti-VEGF injection, VA 20/50; 
f –recurrence during deteriorated foot ulcer, HbA1c 9% VA 20/150; g –one month after anti-VEGF intravitreal 
injection, VA 20/50; h –OCTA superficial plexus-decreased central perfusion  by 54% in 6 months after 4 
major recurrences; i –advanced OND pallor, macrocystsand atrophic areas in the macula, severe ischemia 
and NVE.
Figure 3. 
60 years old female, 20 years of poorly controlled DM, arterial hypertension; multiple recurrences of 
perimacularedema, NPDR. a –One month after anti-VEGF injection, VA 20/20; b –treatment interrupted 
for 8 months, VA 20/30, 5 months after hysterectomy; c –one month later after anti-VEGF, VA 20/20;  
d, e–3 months later-new recurrent intraretinal edema progressing towards the macula, new ischemic areas, 
VA 20/30, f, g–one month after anti-VEGF injection and focal laser, persistent perimacular ischemia,  
VA 20/20.
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of the foveolar avascular zone and has been correlated with increasing severity of 
the retinopathy, especially in patients with proliferative disease (Figure 6). The 
presence of DRIL can be associated with disorganized outer retinal layer disruption, 
Figure 4. 
57 years old female, DM for 25 years, sleeve gastrectomy, chronic cholecystitis, CAD, DME, PDR, secondary 
glaucoma. a –after 3 anti-VEGF injections and 1 OzurdexVA 20/60, cataract; b –deteriorated edema with 
subsensory fluid 14 days after phacemulsificationVA 20/60; c − 14 days after anti-VEGF injection, VA 20/30; d – 
recurrent edema during CABG, subsensory fluid, hyperreflective foci VA 20/40; e –severe edema after pyocele and 
sepsis, VA 20/40; f –recurrence after stroke, VA 20/30; g − 7 days after Ozurdex, VA 20/25; h –severe recurrence 
3 months after the second Ozurdex, VA 20/40; j –rapid response to Iluvien, VA 20/25; k –microperimetry-decreased 
central retinal sensitivity, unstable central fixation; l -decreased central perfusion in the superficial plexus by 46% 
in 18 months; m –microcystic edema and hard exudates in the macula, stable PDR, visible Iluvien implant.
Figure 5. 
70 years old female. Chronic macular edema, NPDR, chronic uveitis, secondary glaucoma for 12 years, poorly 
controlled diabetes, arterial hypertension, lost for follow up for 4 years. a –Three weeks after intensive topical 
steroids and antiglaucoma medications VA 20/250; b -after 4 anti-VEGF and focal laser –persistent macrocystic 
edema, regressing hard exudates, VA 20/50, c –OCTA –total retina-significant capillary dropout, enlarged 
irregular foveolar avascular zone; d –chronic edema, circinate hard exudates.
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specifically ellipsoid zone (EZ) and external limiting membrane (ELM). Moreover, 
Sun and colleagues have found that an increase in DRIL during 4 months predicted a 
decline of visual acuity by one line [12].
OCT assessment of the vitreomacular adhesions and traction is indispensable 
in the choice of treatment. The presence of anterior–posterior traction is considered 
an indication for pars-plana vitrectomy in eyes with DME, however other OCT 
findings - greater retinal thickness, presence of subretinal fluid, lack of external 
limiting membrane integrity and disruption of the ellipsoid zone - have been 
associated with a poorer final absolute BCVA. [10]. Macular edema in eyes with 
lamellar holes associated with tangential traction needs careful consideration – it 
often responds favorably to intravitreal treatment and may remain stable, however 
should be monitored closely in the presence of active PDR and may eventually 
require surgical management. (Figure 1).
5. Optical coherent tomography angiography
The contribution of OCTA in the assessment of high-risk DME is substantial. It 
will detect capillary dropout, microaneurisms and neovascularization in detailed 
3-dimentional segments (Figure 2a) and provide quantitative estimates of the 
perfusion and vascular density by areas [13] (Figure 4I). A recent study demon-
strated that although there was no significant difference in the superficial capillary 
plexus between anti-VEGF responders and poor responders, poor responders 
tended to show greater damage and more microaneurysms in the deep capillary 
plexus and a larger foveolar avascular zone (FAZ) area. The topographic location 
of the disrupted synaptic portion of the outer plexiform layer in SD OCT exactly 
corresponded to the nonflow area of the deep capillary plexus in OCTA [14]. The 
enlargement and irregularities of the FAZ have to be interpreted carefully in the 
presence of large central cysts as such findings could be associated with capillary 
displacement rather than ischemia, especially in eyes with retained inner and outer 
retinal morphology. OCTA assessment of patients with DME and neurosensory 
detachment demonstrated improvement in cysts area and perfusion density in the 
superficial and deep capillary plexus in response to treatment with Dexamethasone 
and ranibizumab [15]. Persistent microaneurisms and declining perfusion in the 
deep capillary plexus in another comparative work was associated with less vision 
gain and incomplete resolution of the edema after treatment with aflibercept [16].
Figure 6. 
60-years old female, 20 years of poorly controlled diabetes. Phacoemulsification and vitrectomy, choroidal 
effusions. a -Severe DME, epiretinal membrane, DRIL one month after surgery; b − 4 months later after 3 
anti-VEGF injections –incomplete, unstable response; c − 6 months later after 2 Ozurdex implants –residual 
perimacular degenerative fluid spaces; d –persistent macular edema, mild DRIL, epiretinal membrane, hard 
exudates and microaneurisms.
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6. Fundus autofluorescence
Short-wavelength FAF derives its signal mainly from lipofuscin in the RPE. Long 
wavelength autofluorescence or near-infrared FAF derives its signal from melanin, 
which is present in RPE and choroid. Intraretinal cysts in DME unmask the under-
lying RPE by displacing the luteal pigment in the fovea and this prevents the normal 
blockage of foveal FAF signal. Granular and patchy hyper- and hypo-autoflurescent 
lesions in the parafoveolar area have been described and correlated with foveolar 
cystoid spaces in DME patients. Larger area of hyper-autofluorescence in eyes 
with higher number of hyperreflective foci and presence of subfoveal neuroretinal 
detachment may indicate a prevalent inflammatory condition in DME with specific 
response to steroidal treatment [17, 18].
7. Microperimetry
Micoperimetry is able to quantify macular sensitivity and fixation pattern 
in an exact, fundus-related fashion, thus adding detailed information about 
the degree and pattern of macular function alteration (Figure 4k). It has been 
successfully used in the diagnosis and follow-up of different macular disorders, 
including age-related macular degeneration, myopic maculopathy, macular 
dystrophies, and diabetic macular edema. Vujosevic S et al. have demonstrated in 
a series of studies that macular sensitivity is significantly affected when diabetic 
macular edema develops and it deteriorates further in eyes at more severe stages 
of macular edema even in the absence of ischemia. The stability of the fixation is 
decreasing late in the disease and indicates advanced photoreceptor damage and 
chronicity [19].
8. Glaucoma in eyes with DME
In a recent meta-analysis of prospective cohort studies the pooled risk ratio of 
the association between primary open-angle glaucoma (POAG) and diabetes was 
1.36 [20] The prevalence of glaucoma in diabetics ranges from 4.96% to 14.6% with 
significant variations in geographic regions and racial groups. Moreover, there is a 
statistically significant association between the duration of diabetes and glaucoma. 
[21]. Hou et al. compared rates of visual field (VF) loss and retinal nerve fiber layer 
thinning for patients with POAG and found no difference in progression between 
patients without and with type 2 diabetes and no detectable diabetic retinopathy. 
They also found that treated diabetes was linked to significantly slower loss of 
RNFL thickness [22].
The risk of ocular hypertension in a patient presenting with DME needs to be 
considered in the treatment choice. While anti-VEGF agents are generally safe, a 
key DRCR.net report on eyes with center-involved DME and no preexisting open-
angle glaucoma treated on ranibizumab and monitored for 3 years demonstrated 
increase in the risk of sustained IOP elevation or the need for ocular hypotensive 
treatment after anti-VEGF treatment [23]. In patients with POAG and DME treated 
with ranibizimab and monitored for 24 months, Fursova et al. report a decrease 
in the functional and structural parameters of the retina and optic nerve, and a 
higher rate of progression of glaucomatous optic neuropathy compared to patients 
without DME. Long-term results have not revealed a significant deterioration in the 
structural parameters of the optic disc and retina as a consequence of anti-VEGF 
therapy [24].
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Intravitreal steroids will induce hypertensive response in up to 50% of the eyes 
with DME. The MEAD Study reported that over 40% of eye required initiation of 
a topical ocular hypotensive agent and 0.3% of eyes required incisional glaucoma 
surgery after Ozurdex. [25] In the FAME Studies, 18.4% of eyes that were injected 
with the 0.2 μg Iluvien-FA per day implant developed an IOP higher than 30 mmHg 
and 4.8% underwent incisional glaucoma surgery [26]. After a follow-up of 5 years, 
9% of eyes that had multiple injections of triamcinolone acetonide required a trab-
eculectomy [27]. An eye that does not develop substantial IOP elevation after a chal-
lenge course with a topical steroid may still respond with an IOP rise after Ozurdex or 
Iluvien, however in most cases it is well controlled on antiglaucoma medications [28].
Patients with refractive DME and well compensated glaucoma on one or two 
antiglaucoma drops responded favorably to both Ozurdex and Iluvien in our prac-
tice. (Figure 4) An eye with advanced glaucoma on more than 2 medications is at a 
high risk of uncontrollable IOP and severe vision loss after intravitreal steroid, and 
glaucoma surgery has to be performed prior to the switch from anti-VEGF.
Neovascularization of the iris or neovascularization of the angle that ultimately 
lead to neovascular glaucoma is a consequence of long-standing ischemia in patients 
with PDR. The incidence of neovascular glaucoma is further increased in patients 
who have undergone vitrectomy and lensectomy. Breach of the posterior capsule 
from a complicated cataract extraction or even from Nd: YAG laser capsulotomy 
may allow angiogenic factors to gain access to the anterior segment more readily, 
accelerating formation of neovascularization. The management of DME in these 
eyes with intravitreal anti-VEGF provides temporary regression of the iris neovas-
cularization, decrease in the PDR severity and facilitates the panretinal photocoag-
ulation [29]. Early glaucoma surgery significantly improves the visual prognosis of 
DME in eyes with neovascular glaucoma, however they remain at high risk of IOP 
decompensation, reactivation of the PDR and recurrences of the macular edema 
and need prompt, often urgent treatment.(Figure 2).
9. Uveitis
History of a previous uveitis episode or evidence of a chronic intraocular inflam-
mation in a patient with DME heralds high rate of complications and difficult man-
agement (Figure 5). A large database from the UK was analyzed for the prevalence 
of acute uveitis over a six-year period among populations without (n = 889,856) 
and with diabetes (n = 48,584) and evaluated the impact of glycaemic control on 
disease risk. Poor glycaemic control increases the risk of acute uveitis, with patients 
that have an HbA1c over >11.3% almost 5 times more likely to have an event. Acute 
uveitis was also more common in those with proliferative retinopathy. The odds 
ratio (OR) for acute uveitis was significantly higher in patients with type 1 DM (OR 
2.01), Black (OR 20.17) or Asian (OR 2.09) ethnicity, proliferative disease (OR 2.42) 
and escalated with increasing HbA1c, however the association with maculopathy 
was less - OR 1.15. [30]. In a cohort of middle-aged diabetic patients with uveitis, 
who were followed up for 4 years, 42% had final visual acuity worse than 6/18. In 
53% of the eyes, the poor visual acuity was thought to be uveitis related, and a half 
of these eyes had clinically significant macular edema. Progression of diabetic reti-
nopathy to proliferative stage occurred in 10% of the eyes. In patients with available 
HbA1c data, the levels were over 7.0% on almost all cases in the quiescent period 
and rose by 1.5–4% in the acute episodes. The authors conclude that uveitis occur-
ring in patients with pre-existing diabetes can be associated with numerous ocular 
complications and recurrences. Macular involvement related to both the uveitis and 
the diabetes appears to be the main cause of reduced vision [31].
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In clinical practice, diabetic patients with macular edema and uveitis have higher 
tendency to develop fibrinous exudates in the anterior chamber and posterior syn-
echiae, particularly after intraocular surgery. They respond favorably to topical, peri-
ocular and intravitreal steroids and require close monitoring for intraocular pressure 
spikes. Interestingly, the IOP in many patients with uveitic glaucoma decreases in 
response to appropriate anti-inflammatory management; in the meantime the macu-
lar edema deteriorates, particularly if the patient is on systemic steroids or a biologi-
cal agent and with significant fluctuations in the glucose levels. The recurrence of the 
edema may remain unnoticed in eyes with media opacities and active inflammation 
and is “discovered” once the uveitis subsides in the search for explanation of the poor 
vision - severe macrocysts in the macula are usually accompanied by exudative sub-
sensory fluid collections. Early detection of the DME while the visual acuity is still 
reasonable and prompt intensive intravitreal treatment improve greatly the visual 
prognosis (Figure 5). These patients are very unstable - they present frequently with 
recurrent uveitis and macular edema in the course of each attack of their systemic 
inflammation or in periods of deteriorated metabolic control.
10. Cataract surgery and DME
Cataract surgery in diabetic patients has been associated with higher risk of 
complications, including postoperative macular edema (Irvine-Gass syndrome) 
and worsening of pre-existing DME (Figure 4b). The risk is high in patients with 
inconsistent previous treatment or chronic edema with incomplete response to 
intravitreal management. The prevalence is increased by intraoperative vitreous 
loss, vitreous traction at incision sites, vitrectomy for retained lens fragments, iris 
trauma, posterior capsule rupture, intraocular lens dislocation, early postoperative 
capsulotomy, iris-fixated intraocular lenses and placement of an anterior chamber 
intraocular lens and is further exaggerated by persistent postoperative inflamma-
tion [32, 33]. In clinical practice the edema is usually revealed late in the postopera-
tive period and the differentiation between pseudophakic cystoid (Irvin-Gass) and 
macrocystic diabetic edema may not be very straightforward on OCT. The presence 
of hard exudates, atrophic changes and hypoperfusion in the posterior pole and 
some degree of retinopathy in an eye with low vision is more suggestive of a DME 
(Figure 5) while better vision and characteristic fluorescein angiography findings 
like retinal telangiectasis, capillary dilatation, and leakage from perifoveal capil-
laries in the early phase frames, and perifoveal hyperfluorescent spots classically 
described as a “petalloid” pattern in the late phase frames are suggestive of pseu-
dophakic cystoid macular edema. While in most cases, acute pseudophakic CME 
spontaneously resolves with relatively good vision, the eyes with deteriorated DME 
after cataract surgery remain with low vision despite vigorous treatment on intra-
vitreal anti-VEGF and steroids. There is a general consensus that DME and severe 
diabetic retinopathy should be stabilized before undergoing cataract extraction and 
proactive management is recommended in preparation for surgery. Recurrence or 
worsening of DME has been successfully prevented by preoperative or intraopera-
tive ranibizumab [34] and triamcinolone acetonide (TA) [35], however the efficacy 
was short lasting and a sizable group of the eyes with TA develop elevated IOP. 
Dexamethasone implants have been used intraoperatively and postoperatively [36, 
37], however if inserted 2 to 4 weeks prior to surgery they reach their peak activ-
ity at the time of the procedure and help control the postoperative inflammation. 
The initial improvement in visual acuity and decrease in the edema in the first 
1–2 months start deteriorating in the next 2–3 months, yet these eyes respond favor-
ably to repeated dexamethasone treatment [38].
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11. Diabetic macular edema after vitrectomy
The development and use of smaller gauge instrumentation has been associated 
with a trend towards earlier surgical intervention for diabetic retinopathy. PPV 
indications  include non-clearing vitreous hemorrhages, traction retinal detach-
ment in PDR, and vitreoretinal interface abnormalities impeding macular edema 
resolution. The role of pars plana vitrectomy (PPV) for eyes with DME without 
traction elements is less clear. Debate still exists as to the necessity of ILM removal 
during vitrectomy for DME [39]. Several studies over the past 3 decades have 
established the structural improvements following vitrectomy in recalcitrant DME 
cases. Visual improvements however have not been as consistent and as significant 
as the reduction in retinal thickness following the procedure. Surgical intervention 
continues to be reserved for those cases that have had chronic and severe forms of 
DME when retinal damage is usually irreversible thereby compromising the results. 
[40]. Vitrectomy itself is associated with morphological changes in the posterior 
pole. Detailed evaluation of the macular microstructure after vitrectomy has 
demonstrated deteriorated photoreceptor outer segment (PROS) length, ellipsoid 
zone (EZ) and external limiting membrane (ELM). The postoperative recovery was 
uneven – while PROS increased significantly after 12 months, ELM recovered but 
did not improve by 24 months when compared to baseline, and the EZ continued 
improving up to 24 months. [41, 42]. Another factor contributing to lower postop-
erative visual results is post-vitrectomy cystoid macular edema that ranges between 
5–47% and has been associated with combined cataract surgery, silicone oil tam-
ponade and its removal, and removal of retained lens fragments in the diabetic 
eye. This inflammatory condition needs to be differentiated from a recurrence of 
pre-existing DME after PPV. The presence of dense hard exudates, disorganized 
retinal layers in the edematous macula, paramacular laser spots, capillary drop-
out on OCTA and persistent ischemic changes anywhere in the retina indicate the 
increased risk of poor postoperative vision, however, early intensive management 
on intravitreal steroids and anti-VEGF combined with careful laser treatment will 
significantly improve the prognosis (Figure 6). A recent meta-analysis estimated 
the overall pooled incidence of neovascular glaucoma (NVG) after PPV in PDR 
patients at 6%. The study showed a positive correlation for NVG after PPV in PDR 
patients with higher baseline IOP, preoperative iris neovascularization, lack of 
panretinal photocoagulation, preoperative or intraoperative combined cataract sur-
gery, postoperative vitreous hemorrhage and a negative correlation with age [43]. 
Persistent macular edema in these eyes is a therapeutic challenge. Early glaucoma 
valve surgery with perioperative anti-VEGF, followed by appropriate intravitreal 
treatment can stabilize these eyes despite the grave prognosis, moreover that suc-
cessful combined management of DME correlated closely with long-term recovery 
of photoreceptor integrity and visual outcome in patients with resolved DME in the 
presence of retained vascular density in the deep capillary plexus [44].
12. Age
The participants in Protocol T were enrolled at an average age of 61 years 
[45–58]. Secondary analysis of the baseline factors associated with visual out-
come after 2 years of intensive anti-VEGF treatment revealed that even in such 
a relatively young cohort with every decade of age the scope of mean visual 
improvement decreased by 2.1 EDTRS letters. When the change in visual acu-
ity over 2 years was estimated longitudinally as area under the curve (AUC), 
the improvement was reduced by 1.9 letters for each decade of life. [9]. This 
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association supports previous findings from DRCR.net Protocol I on treatment 
with a single anti-VEGF [59] and the RISE and RIDE trials where the odds of 
achieving at least a 15-letter gain at 2 years fell for every 5-year increase in the 
age of the patients.
13. Glycemic control
There is controversy on the correlation of HbA1c and visual response to anti-
VEGF from large phase 3 trials. An analysis of ranibizumab-treated patients from 
the RISE and RIDE trials did not find an association between mean change in 
BCVA at weeks 52 and 100, with the baseline HbA1c [60]. This is in contrast to an 
analysis of aflibercept-treated patients from the VISTA and VIVID trials, which 
found that the mean improvement in VA at 2 years was dependent on HbA1c levels 
[61]. An exploratory analysis of DRCR.net Protocol T, in which participants were 
randomized to receive bevacizumab, ranibizumab, or aflibercept, found that the 
magnitude of vision improvement after anti-VEGF treatment decreased by 1 letter 
for each 1% increase in HbA1c levels at baseline [9]. More recently, lower HbA1c 
levels at baseline (7% or less) were significantly associated with greater reduction 
in central macular subfield thickness at one month after injection of bevacizumab 
or ranibizumab, however the change in BCVA after treatment did not have any 
correlation with the glycemic control [62]. Chen et al. reported that after one 
year of treatment on ranibizumab, only in the responder group the baseline level 
of HbA1c was significantly associated with the changes in BCVA and the final 
BCVA. [63]. The common methodological issue with these trials and cohorts 
under observation is the estimate of glycemic control – HbA1c at baseline, only. 
There is a significant variability in the glucose plasma levels in diabetic patients. 
Its impact on microvascular complications in type 2 diabetes was investigated in a 
post-hoc analysis of 12 042 participants in both Action to Control Cardiovascular 
Risk in Diabetes (ACCORD) and the Veteran Affairs Diabetes Trial (VADT) that 
were observed for 84 to 87 months. Variability measures included coefficient 
of variation and average real variability for fasting glucose. Both indices were 
associated with development of future microvascular outcomes - higher risk of 
developing PDR that requires laser treatment - even after adjusting for other risk 
factors, including measures of average glycemic control (ie, cumulative average 
of HbA1c). Meta-analyses of these 2 trials confirmed these findings and indi-
cated fasting plasma glucose variation may be more harmful in those with less 
intensive glucose control [64]. A patient with DME and significant fluctuations 
in the plasma glucose, hypoglycaemic episodes and HbA1c over 7.5% needs close 
monitoring – even though the edema may respond structurally to intravitreal 
treatment, the visual outcome will be limited and very unstable. In addition to 
the ubiquitous dietary mistakes and sedentary lifestyle, often there are problems 
associated with ongoing infections, diabetic foot ulcers, non-ocular surgeries 
and systemic steroid treatment (Figures 2 and 4) Dynamic fasting and random 
plasma glucose and HbA1c re-assessment at the clinic and prior to intravitreal 
treatment are easy and useful in identifying these patients, particularly during 
worsening of the DME and diabetic retinopathy after periods of stabilization.
14. Cardiovascular disease
The association between cardiovascular disease and diabetic retinopathy was 
studied mainly in patients with mild retinal lesions. A recent meta-analysis was 
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performed on 7604 individuals with type 2 diabetes from 8 prospective population-
based surveys that were monitored for 5.9 years (3.2 to 10.1 years) where DME 
was identified in retinal photographs. DME was observed in 0.5% to 7.6% of the 
participants and was related to an increased risk of first-ever cardiovascular disease 
- incidence rate ratio 1.65 and fatal cardiovascular disease - incidence rate ratio 2.85. 
The incidence rate ratio for first-ever coronary heart disease was 1.57 and for fatal 
coronary heart disease - 3.55. These associations were consistent after multivariable 
adjustment for vascular risk factors, including smoking, systolic blood pressure, 
use of hypertension medication, total cholesterol level, and body mass index. When 
duration of diabetes, use of treatment for diabetes, and glycosylated hemoglobin 
level were included in the multivariable model, the relationship remained signifi-
cant [65]. This analysis resonates with an early report on markers for subclinical 
cardiovascular disease in diabetic patients: CSME was associated with a high coro-
nary artery calcium score (odds ratio, OR 2.86), low ankle-brachial index (OR 4.08) 
and high ankle-brachial index (OR 21.4) after adjusting for risk factors including 
hemoglobin A1c level and duration of diabetes, but there was significant association 
with carotid intima-media thickness or carotid stenosis, defined as >25% stenosis or 
presence of carotid plaque [66]. The diagnosis of CSME in these studies was based 
on fundus photographs; had OCT been used as a more sensitive imaging modality 
[13, 45, 67], the proportion of DME patients with increased cardiovascular risk 
could have been even higher. In clinical practice, confirmed or probable decom-
pensated coronary artery disease is usually associated with more severe retinal 
ischemia, unstable response to treatment and higher risk of cardiovascular compli-
cations after intravitreal anti-VEGF if used in the course of an acute episode. The 
extent of macular edema and rate of its recurrence decrease notably after successful 
angioplasty or coronary bypass graft, however these patients remain at high risk as 
they are prone to new coronary heart attacks, severe infections and vision-threat-
ening complications – neovascular glaucoma, ischemic diabetic optic neuropathy, 
vitreous hemorrhages and chronic macular edema (Figures 1, 3 and 4).
15. Diabetic nephropathy and hemodialysis
Chronic kidney disease has been related with progression to PDR and DME 
in type 2 diabetic patients in advanced stages of their microvascular impairment. 
Systematic assessment of 2135 type 2 diabetic patients for 8 years revealed in 9.2% 
of new-onset DME identified in fundus photographs that had meaningful relation-
ship with albumin/creatinine ratio below 31 mg/g at baseline, mean follow- serum 
creatinine levels and estimated glomerular filtration rate 30 and 45 mL/min/1.73 m2 
[46]. This longitudinal study clearly emphasizes the importance of screening the 
DME patients for abnormal renal profile at baseline and throughout the whole 
follow up. A marked VEGF expression secondary to glomerular injury and elevated 
levels of serum VEGF in patients with advanced nephropathy could explain the 
incomplete and unstable response of their macular edema to intravitreal treatment. 
Introduction to hemodialysis of patients with end-stage renal disease and coexist-
ing DME was associated with significant reduction in the central retinal thickness 
lasting over the next 12 months, to a level that eliminated the need for intravitreal 
treatment in 93.2% of the eyes. The fluid resolution was greater in eyes with sub-
retinal detachment compared to spongelike swelling and macrocystic edema. A 
significant correlation between changes of BCVA and central retinal thickness at 
12 months after hemodialysis initiation was found in the patients with good BCVA 
(over 20/50) but not in the patients with poor BCVA (less than 20/50) [47]. In 
clinical practice, a sizable group of patients with advanced renal decompensation 
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had notable stabilization of their DME after induction of hemodialysis and needed 
less intensive management, however they remain at high risk for recurrences of the 
edema and severe retinal ischemia (Figure 7).
16. Treatment plan
Patients with DME at high risk for complications and vision loss require close 
monitoring at short intervals, intensive flexible treatment and arrangements for 
urgent visits and referrals. Very often, the patients present with multiple oph-
thalmic and systemic risk factors or develop them while they are under our care. 
Unrecognized and poorly treated complications and their exacerbations will readily 
explain the lack of results after “routine” management. Instead of labeling the 
patient as “non-responder” and giving up treatment altogether, or waiting for the 
inevitable vision deterioration in order to “start reacting”, a “proactive” approach is 
more effective to achieve high and stable visual acuity, even in difficult patients.
17. Early start with high visual acuity
Initiation of treatment in high-risk eyes with BCVA better than 20/40 (Decimal 
0.5, LogMAR 0.3) has resulted in better response and higher visual outcome in 
short- and long term. In our cohort of 152 eyes, 82.89% had BCVA 20/40 at their 
final visit after 3 to 8 years of management. Out of 126 eyes with BCVA 20/40 and 
better prior to treatment, 76.96% retained it through the follow up, however only 
34.63% of the eyes with BCVA 20/50 and less could improve to 20/40 and better. 
Final BCVA 20/150 and less (the level of legal blindness in Kuwait) was seen in 
4.82% of the eyes with high initial visual acuity and in 23.06% in the eyes with 
worse baseline vision.
18. Early start in eyes with perimacular edema
Recent or chronic edema close to the macula seldom affects the visual acuity, how-
ever it tends to progress centrally after major non-ocular surgeries, severe infections 
Figure 7. 
59 years old male, DM for 25 years, renal failure, chronic hemodialysis, CAD, DME, PDR, recurrent anterior 
uveitis, recurrent iris neovascularization, secondary glaucoma. a, b -Perimacular edema progressing centrally 
during deterioration of CAD and CABG, VA 20/20, c − 6 months and 4 intravitreal injections later, VA 20/20, 
d - OCTA –superficial plexus, capillary dropout, microaneurisms, hyperreflectivefoci and distorted enlarged 
foveolar avascular zone.
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and exacerbations of cardiovascular and renal complications (Figures 3, 4 and 7). 
Early intravitreal treatment is usually effective and results in high visual acuity – in our 
cohort, 40% of the eyes with final BCVA 20/40 and better had significant perimacular 
edema at baseline. In eyes with more distant chronic lesions where persistent leakage 
and hypoperfusion are evident, intravitreal treatment can be followed by delicate focal 
laser once the edema has regressed. The classical perivascular technique of P. Hamilton 
performed with the 50 micrometer spot and minimal power settings applied in the 
temporal half of the posterior pole is suitable in severe chronic cases.
19. Severe NPDR and PDR in an eye with DME
Nowadays these patients seldom come without any previous treatment. 
Incomplete retinal laser and particularly interrupted intravitreal anti-VEGF injections 
for PDR have resulted in sight-threatening complications. PRP, primary vitrectomy 
or pharmacotherapy, alone or in combination, have been proposed with excellent 
outcome. The choice greatly depends on the ability of the patient to visit the clinic 
for regular follow up or emergency. Serious comorbidities and psychiatric diseases 
are associated with lengthy admissions and recuperation – and lack of eye treatment. 
Such patients will benefit from completion of the PRP and a longer-acting intravitreal 
medication while they are still ambulant. The main concern with PRP is the periph-
eral visual field (VF) loss associated with photocoagulation burns. A recent ad hoc 
review of DRCR.net Protocol S data reports decline of the pericentral and peripheral 
visual field 5 years after treatment with 20 ranibizumab injections to a level close 
to the pattern in eyes with PRP and 7 ranibizumab injections, suggesting that there 
are factors besides PRP associated with VF loss in eyes treated for PDR. In the longi-
tudinal model describing total VF point score loss, the amount of loss depended on 
the type of laser treatment applied. On average, additional PRP sessions were associ-
ated with less VF loss than an initial PRP session, and endolaser application during 
vitrectomy was associated with more loss than an initial PRP session. The losses may 
be direct and immediate effects of heavier vs. lighter photocoagulation or reflections 
of delayed deleterious effects of the treatments, conditions associated with the per-
sistence or return of neovascularization necessitating additional treatment, cataract 
progression, or, in the case of endolaser with vitrectomy, adverse effects of vitreous 
hemorrhage or the surgical procedure, such as cataract [48]. In practice, early, gradual 
and sparing laser technique with smaller spot size and less duration, particularly after 
intravitrel pharmacotherapy, is seldom associated with significant field loss – these 
defects appear after severe ischemia and correspond to non-perfusion areas.
20. Anti-VEGF medications as first choice
Abundant published data emphasize the safety of all off-label and approved 
drugs. Ranibizumab (Lucentis®, Novartis, Basel, Switzerland) and Aflibercept 
(EYLEA®; Bayer HealthCare, Berlin, Germany/Regeneron Pharmaceuticals Inc., 
Tarrytown, NY, USA) are preferable as initial treatment for eyes with DME and 
primary or secondary glaucoma, however the IOP needs close monitoring for 
spikes if larger volume has been injected intravitreally. This class of antibodies 
induces regression of the iris neovascularization and resolution of intraretinal 
edema and hemorrhages in eyes with PDR and this facilitates greatly the comple-
tion of PRP. An important consideration is the partial response and persistence 
of macular edema - data from Protocol T demonstrated chronic fluid in up to 
65.9% of the eyes on bevacizumab, in 44.2% of the eyes on ranibizumab and 
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39.2% of the eyes on aflibercept after 2 years of treatment [1].The number of 
intravitreal injections during the first year is decisive – in Protocol T, after the 
loading dose, the eyes that ended up with chronic edema had on average 3 injec-
tion from the 24th to 52nd week vs. 6 injections in eyes without chronic DME 
for the same period. Even though the eyes with chronic edema were given 4 to 6 
injections during the second year, they remained with persistent fluid, unlike the 
eyes without fluid after the first year – they maintained relative stability on 2–3 
injections during the second year [1]. The ability of a high-risk patient to com-
plete such an intensive treatment, particularly if the edema is bilateral, needs to 
be discussed beforehand.
21. Intravitreal dexamethasone as first choice
The use of Dexamethasone intravitreal implant (0.7 mg) (Ozurdex, Allergan, 
Inc., Irvine, CA, USA) in eyes with DME, alone or in combination with anti- VEGF 
drugs, vitrectomy and retinal laser has been studied extensively since 2011. The 
implant provides rapid resolution of the macular fluid in all compartments that 
is sustained oved the next 2–4 months. It decreases the existing hard exudates 
and prevents the formation of new ones [49], and reportedly reduces the rate of 
progression of retinopathy [50]. Dexamethasone implant is selected as primary 
treatment in patients with recent and severe cardiovascular complications or 
pregnancy where the risk of systemic side effects from anti-VEGF injections 
needs to be avoided. Severe chronic maculopathy is often refractory to anti-VEGF 
management and a trial loading dose with these drugs may turn out to be an 
unnecessary delay. A dexamethasone implant as initial treatment might be a better 
choice for such patients, moreover that treatment–naïve eyes consistently fared 
better that eyes on long previous non-steroidal management. The main concerns 
are the formation of cataract in phakic eyes and elevation in the IOP. In the MEAD 
studies, the incidence of cataract-related side effects was 67.9% in the 0.7 mg dexa-
methasone implant and the rate of cataract surgery was 59.2%. In the same trial, 
an increase in IOP was observed in 27.7% of the eyes and 1.4% of them required a 
glaucoma procedure (trabeculoplasty, iridotomy, iridectomy, or trabeculectomy) 
[51]. A patient with advanced glaucoma, even well compensated on topical treat-
ment or after glaucoma surgery, is at risk of developing further optic nerve disc 
damage and vision deterioration after a steroid- induced IOP spike. A short trial 
use of dexamethasone drops 4–5 times daily readily provokes a meaningful IOP 
elevation in a steroidal responder and foretells similar issues with the implant. In 
clinical practice, an increase in the IOP is observable a week after implantation 
and responds well to topical beta blockers and carbonic anhydrase inhibitors. The 
IOP needs monitoring for at least three months as in some cases it decreases after 
resolution of the implant, and in others it remains permanently high and requires 
consistent glaucoma care. The DME patients with glaucoma on intravitreal dexa-
methasone in our practice remained controlled on topical medications and none 
needed glaucoma surgery. The progression of cataract after several dexamethasone 
implants and the need for surgery as part of the vision rehabilitation has to be 
discussed with the high-risk patients beforehand - in most cases the possibility of 
good functional results outweigh the apprehension and fear (Figures 4 and 6). In 
vitrectomized eyes with aphakia, large iridectomies, zonulolysis, large peripheral 
defects in the posterior lens capsule and dislocated IOLs the implant tends to 
migrate in the anterior chamber and induce elevated IOP and corneal edema to a 
point that may require a corneal graft. A peribulbar depo-steroid might be a safer 
option in such complicated eyes.
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22. Vitrectomy as first choice
The introduction of small gauge platforms and refined instrumentation have 
greatly improved the safety and reliability of PPV as primary treatment for eyes 
with DME and vitreomacular traction. The role of primary PPV for eyes with DME 
without traction elements is less clear. An earlier publication of Michalewska Z et al. 
[52] on 20-G vitrectomy and ILM removal, the multicenter trial of Iglicki M et al. 
[53] using 25-G PPV and ILM peeling and the report of Lin HC et al. [54] on 23-G 
vitrectomy with ILM peeling as a first line treatment for DME demonstrate substan-
tial increase and stabilization of visual acuity, macular fluid resolution and rapid 
regression of hard exudates, without additional therapy up to 24 months post sur-
gery. Prognostic factors associated with a greater visual gain include no history of 
prior macula laser treatment, lower hemoglobin A1c, recent onset of the edema and 
younger age, however delay of the procedure and damage of the IS/OS and ellipsoid 
zone at baseline had negative effect on the vision gain 12 and 24 months postopera-
tively. The complications after PPV can not be ignored – lamellar and full-thickness 
macular holes, non-resolving preretinal hemorrhages and rhegmatogenous retinal 
detachments have all been reported, and up to 50% of the phakic eyes develop 
significant cataract during the next 12 to 24 months that requires surgery compared 
to 7.14% of the eyes in the pharmacotherapy group [53]. These results suggest that 
earlier intervention with pars plana vitrectomy may be beneficial for treatment- 
naïve eyes, but they need to be replicated in larger prospective controlled trials.
23. Management of diabetes and its complications
Partnership and regular consultations with the diabetologist or treating physician 
are essential part of the management in high-risk DME patients. The adjustments or 
frank replacement of diabetic medications, provision of glycemic monitoring devices, 
lifelong screening for cardiovascular and renal complications, prompt referral to the 
necessary subspecialist create the foundation for better glycemic control, improved 
stability and less severe retinal complications. Regular measurements of HbA1c at 
the retinal clinic and RBS prior to intravitreal injections easily screen patients with 
unsatisfactory glycemic control and have become routine in our practice. Sudden 
worsening of the retinopathy and macular edema are often preceding serious sys-
temic complications and a swift arrangement for medical assessment may prevent a 
major disability or even save the life of the patient (Figure 1). Discussing the medi-
cal background with a patient presenting with relapsing DME reveals sometimes 
bureaucratic and financial barriers to qualified medical care. Direct contacts with a 
dedicated medical team and suitable procedures for referral are particularly helpful in 
challenging situations that need consistent management. Holistic approach, continu-
ous interest and candid conversations with the patients improve substantially the 
compliance and, in the long run, the outcome of DME treatment.
24. First outcome – review and adjustments of the treatment
Careful observation of high-risk eyes one week after the first anti-VEGF intravit-
real injection reveals a degree of fluid resolution (Figure 2c) and its recurrence one 
month later. Rather than lack of response, this indicates ongoing retinal ischaemia and 
the need for tight metabolic control and management of systemic comorbidities. An 
early positive response on OCT may not be associated with immediate improvement 
of the visual acuity, however the monthly injections with the chosen drug need to be 
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continued until the loading dose is completed. Meanwhile, if patient and physician have 
decided to perform further laser treatment for eyes with PDR and severe ischemia, it is 
split in suitable intervals. Intensive metabolic control - and the much needed changes 
in the diet – are usually followed by short episodes of hypoglycemia and deterioration 
of the retinopathy severity and recurrences of the edema. The patients need to be 
prepared for this difficult initial period in order to comply with the visits and pro-
cedures without anxiety and confusion. Monthly monitoring of eyes with advanced 
maculopathy is highly advisable – edema that is persistent after one or two anti-VEGF 
injections and is associated with large cysts, hyperreflective spots and particularly 
progressive disorganization in the outer retinal layers indicate severe disruption of the 
blood-retinal barrier and active inflammation. Extending the loading dose to 24 weeks 
will not provide better functional or anatomic outcomes and prompt transition to a 
dexamethasone implant at this point will be more beneficial (Figure 4g). At month 
12, the probability of achieving a BCVA improvement of ≥10 letters was reported 
as 3.71 times greater after intravitreal dexamethasone vs. anti-VEGF treatment [55]. 
High-risk eyes with good response to anti-VEGF in terms of vision gain and fluid 
resolution by the end of the 3rd to 4th month, need sufficient number of injections 
and comprehensive medical care in the next years in order to maintain the outcome. 
Patients with high vision and completed intravitreal course in the first 2 years may 
present with recurrences - they are still at high risk – however they continue respond-
ing well to treatment and retain the acuity with minor variations.
An eye with a high-risk DME, good response to dexamethasone implant as ini-
tial treatment and well controlled IOP is already facing recurrence of the edema and 
deterioration of vision after 3 to 4 months (Figure 4h). Insertion of the implant at 
this point reduces the fluctuations in the edema and resulting detrimental changes 
in the outer retina. Improved metabolic control, successful cardio-vascular manage-
ment and particularly, induction into hemodialysis are associated with more stable 
maculopathy – this allows increase the intervals between implants or even transition 
to anti-VEGF on “as needed” regimen.
25. Further management
The eyes with high-risk DME remain unstable even after they have responded 
well to intravitreal treatment. The patients often present with recurrences during and 
after severe systemic infections, major surgeries, trauma and stress. There are also 
fluctuations in the edema associated with variations in the metabolic control, ongoing 
ischemic events in patient with cardiac and renal complication and ocular surgeries. 
The visual acuity of a well treated diabetic eye is not severely affected by the new fluid 
in the first few months, however if left untreated, it causes gradual functional deterio-
ration that may not be reversible. The management of these eyes is oriented towards 
early detection of the recurrences and timely treatment, in parallel with dynamic 
collaboration with the diabetologist in order to control the systemic complications.
Frequent assessment, sufficient number of intravitreal injections and adequate 
treatment of the retinopathy in the first 2 years are critical, and they need to con-
tinue for lifetime in order to maintain the visual outcome. The initial therapy needs 
modifications and combinations in response to the challenges of the disease.
A shift to a longer acting medication needs to be considered for eyes that can not 
remain stable for more than 45–60 days. There are some early results from the KITE and 
KASTREL studies on brolucizumab where 55.1% of the eyes in KESTREL and 50.3% of 
the eyes in KITE remained on a three-month dosing interval through year one, based on 
a treatment approach determined by disease activity assessment. If disease activity was 
detected, the patients were switched to two-month intervals through the end of the first 
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year. [56] Faricimab, the first bispecific antibody to target both anti-Angiopoietin-2 and 
anti-vascular endothelial growth factor (VEGF) was investigated in YOSEMITE and 
RHINE trials as monotherapy for DME. More than 70% of patients achieved every-12-
week or better dosing status at week 52--73.8% in the YOSEMITE study and 71.1% in 
the RHINE study with every 12-week and every-16-week dosing [57].
Temporary use of dexamethasone implants is convenient for systemically 
unstable patients or in preparation for major surgeries or ocular procedures - this 
will reduce the probability of severe inflammation and macular edema, provided 
the patient is able to use the antiglaucoma drops.
A patient with favorable response to dexamethasone is a good candidate for 
an intravitreal fluocinolone sustained-release Implant (Figure 4g and m). Two 
parallel, prospective, randomized, sham injection-controlled, double-masked, 
multicenter clinical trials (FAME trials) demonstrated significant reduction of the 
central macular thickness, mean BCVA improvement and a higher proportion of 
patients achieving a BCVA improvement of ≥15 letters in eyes with the implant vs. 
sham. The need of glaucoma surgery was 3.7% and 0.5% in the implant and sham 
groups, respectively. [58] A comparison of the effectiveness and safety of the fluo-
cinolone acetonide intravitreal implant between the observational Iluvien Clinical 
Evidence study in the United Kingdom (ICE-UK) and the Fluocinolone Acetonide 
in Diabetic Macular Edema (FAME) randomized controlled trials (RCTs) in people 
with diabetic macular edema demonstrated statistically significant improvements 
in visual acuity 12 months after implantation in both the real-world study and in 
the RCTs. The improvement in vision and central retinal thickness in the RCTs was 
marginally greater than in the real-world study; however, recruits in the real-world 
study had more severe visual morbidity at baseline. [68].
Flexible arrangements for walk-in visits or open appointments prevent delays in 
the evaluation of patients missing their regular review or presenting with a deterio-
ration. Leaving a few empty slots for such unplanned patients in the daily schedule 
decreases the disorder in the medical retina clinic. A registry of the DME patients 
is useful in tracking any lapse in treatment of 3 months or longer that increases the 
probability of poorer outcome.
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